Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
297.78 USD | -3.26% |
|
+4.84% | +14.25% |
Feb. 06 | Daiwa Securities Adjusts Amgen's Price Target to $350 From $360 | MT |
Feb. 06 | Trump faces pressure from US industry over China tariff on medicines | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 22.2B | 24.24B | 24.3B | 24.8B | 26.91B | |||||
Other Revenues, Total | 1.16B | 1.18B | 1.68B | 1.52B | 1.28B | |||||
Total Revenues | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B | |||||
Cost of Goods Sold, Total | 4.36B | 6.16B | 6.45B | 6.41B | 8.42B | |||||
Gross Profit | 19.01B | 19.26B | 19.52B | 19.92B | 19.78B | |||||
Selling General & Admin Expenses, Total | 5.15B | 5.73B | 5.37B | 5.41B | 6.17B | |||||
R&D Expenses | 4.12B | 4.21B | 4.82B | 4.43B | 4.76B | |||||
Other Operating Expenses | 19M | - | - | - | 690M | |||||
Other Operating Expenses, Total | 9.28B | 9.94B | 10.19B | 9.85B | 11.61B | |||||
Operating Income | 9.72B | 9.33B | 9.34B | 10.07B | 8.16B | |||||
Interest Expense, Total | -1.29B | -1.04B | -1.2B | -1.41B | -2.88B | |||||
Interest And Investment Income | 587M | - | - | - | - | |||||
Net Interest Expenses | -702M | -1.04B | -1.2B | -1.41B | -2.88B | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | 110M | 323M | -245M | -233M | 42M | |||||
Other Non Operating Income (Expenses) | - | -324M | 978M | -180M | 1.13B | |||||
EBT, Excl. Unusual Items | 9.13B | 8.29B | 8.87B | 8.25B | 6.46B | |||||
Restructuring Charges | -47M | - | -194M | - | -267M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 56M | 33M | -474M | -479M | 1.44B | |||||
Gain (Loss) On Sale Of Assets | - | - | - | -503M | - | |||||
Asset Writedown | - | - | - | - | - | |||||
In Process R&D Expenses | - | - | -1.5B | - | - | |||||
Legal Settlements | - | -189M | - | - | - | |||||
Other Unusual Items | - | - | - | 78M | 225M | |||||
EBT, Incl. Unusual Items | 9.14B | 8.13B | 6.7B | 7.35B | 7.86B | |||||
Income Tax Expense | 1.3B | 869M | 808M | 794M | 1.14B | |||||
Earnings From Continuing Operations | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | |||||
Net Income to Company | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | |||||
Net Income - (IS) | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | |||||
Net Income to Common Incl Extra Items | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | |||||
Net Income to Common Excl. Extra Items | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 12.96 | 12.4 | 10.34 | 12.18 | 12.56 | |||||
Basic EPS - Continuing Operations | 12.96 | 12.4 | 10.34 | 12.18 | 12.56 | |||||
Basic Weighted Average Shares Outstanding | 605M | 586M | 570M | 538M | 535M | |||||
Net EPS - Diluted | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 | |||||
Diluted EPS - Continuing Operations | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 | |||||
Diluted Weighted Average Shares Outstanding | 609M | 590M | 573M | 541M | 538M | |||||
Normalized Basic EPS | 9.43 | 8.84 | 9.73 | 9.58 | 7.55 | |||||
Normalized Diluted EPS | 9.37 | 8.78 | 9.68 | 9.53 | 7.5 | |||||
Dividend Per Share | 5.8 | 6.4 | 7.04 | 7.76 | 8.52 | |||||
Payout Ratio | 44.75 | 51.69 | 68.1 | 64.04 | 67.83 | |||||
American Depositary Receipts Ratio (ADR) | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |||||
Supplemental Items | ||||||||||
EBITDA | 11.76B | 12.77B | 12.58B | 13.49B | 12.24B | |||||
EBITA | 11.12B | 12.13B | 11.94B | 12.67B | 11.36B | |||||
EBIT | 9.72B | 9.33B | 9.34B | 10.07B | 8.16B | |||||
EBITDAR | 11.93B | 12.96B | 12.78B | 13.67B | 12.42B | |||||
Total Revenues (As Reported) | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B | |||||
Effective Tax Rate - (Ratio) | 14.18 | 10.68 | 12.06 | 10.81 | 14.49 | |||||
Current Domestic Taxes | 1.32B | 955M | 883M | 1.76B | 1.57B | |||||
Current Foreign Taxes | 277M | 277M | 359M | 304M | 786M | |||||
Total Current Taxes | 1.6B | 1.23B | 1.24B | 2.07B | 2.35B | |||||
Deferred Domestic Taxes | -298M | -312M | -317M | -1.21B | -1.15B | |||||
Deferred Foreign Taxes | -6M | -51M | -117M | -63M | -66M | |||||
Total Deferred Taxes | -304M | -363M | -434M | -1.28B | -1.22B | |||||
Normalized Net Income | 5.71B | 5.18B | 5.55B | 5.16B | 4.04B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | 1.29B | 1.26B | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 789M | 962M | 843M | 841M | 647M | |||||
Selling and Marketing Expenses | 789M | 962M | 843M | 841M | 647M | |||||
Research And Development Expense From Footnotes | 4.12B | 4.21B | 6.32B | 4.43B | 4.78B | |||||
Net Rental Expense, Total | 171M | 189M | 199M | 186M | 180M | |||||
Imputed Operating Lease Interest Expense | 54.8M | 49.14M | 56.53M | 56.84M | 78.81M | |||||
Imputed Operating Lease Depreciation | 116M | 140M | 142M | 129M | 101M | |||||
Stock-Based Comp., Other (Total) | 308M | 330M | 341M | 401M | 473M | |||||
Total Stock-Based Compensation | 308M | 330M | 341M | 401M | 473M |